)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Jenburkt Pharmaceuticals
Jenburkt Pharmaceuticals (524731) investor relations material
Jenburkt Pharmaceuticals Q2 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 26/27 earnings summary3 Nov, 2026
Executive summary
Q2 FY27 revenue from operations was ₹4,831.82 lakh and PAT was ₹1,020.94 lakh; H1 revenue was ₹8,383.02 lakh and PAT was ₹1,609.50 lakh.
H1 revenue exceeded ₹8,108.44 lakh in the prior-year period, while H1 PAT was below ₹1,795.52 lakh.
Financial highlights
Q2 total income was ₹5,057.08 lakh; profit before tax was ₹1,433.95 lakh.
H1 total income was ₹8,759.60 lakh and profit before tax was ₹2,110.86 lakh, versus ₹8,522.05 lakh and ₹2,451.40 lakh in H1 FY26.
Q2 EPS was ₹23.13; H1 EPS was ₹36.47, compared with ₹40.68 in H1 FY26.
Segment performance
Operations are exclusively in the pharmaceuticals business segment; segment-wise reporting is not applicable.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Jenburkt Pharmaceuticals
- Q1 FY27 profit after tax declined to ₹588.56 lakhs, with EPS at ₹13.34.524731
Q1 26/27 - Revenue and profit rose, dividend declared, and audit opinion unmodified for FY 2025-26.524731Q4 25/26
- Q3 FY26 saw higher revenue but lower profit after tax and EPS, with added labour cost provisions.524731Q3 25/26
- Revenue and net profit rose year-over-year, with EPS at ₹23.03 and strong cash flow.524731Q2 25/26
- Revenue and profit after tax rose year-over-year, with EPS reaching ₹17.66.524731Q1 25/26
- Strong revenue and profit growth reported for Q2 FY25, with higher EPS and cash flow.524731Q2 24/25
- Q1 FY25 saw higher revenue, profit, and EPS, with continued focus on pharmaceuticals.524731Q1 24/25
- Q3 FY25 saw higher revenue, profit, and EPS, with clean auditor review and pharma focus.524731Q3 24/25
- FY25 net profit rose 23% to ₹3,206 lakh; ₹18/share dividend declared.524731Q4 24/25
Next Jenburkt Pharmaceuticals earnings date
Q3 26/272 Feb, 2027
Jenburkt Pharmaceuticals
Next Jenburkt Pharmaceuticals earnings date
Q3 26/272 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Jenburkt Pharmaceuticals Limited is an Indian pharmaceutical company that manufactures and markets prescription medicines and over-the-counter products. It offers a range of therapeutic solutions in areas such as pain management, anti-infectives, and chronic disease treatments. The company serves domestic and international markets through a network of medical representatives and distribution partners. It is headquartered in Mumbai, India, and its shares are listed on the BSE.